CVM:NYSE.MKT

CEL-SCI Corporation

CEL-SCI Corporation is a Phase 3 cancer immunotherapy company with platform technologies that can potentially treat a variety of cancers and viral diseases. The company is conducting a Phase 3 trial of Multikine (leukocyte interleukin injection) for the treatment of head-and-neck cancer in 17 countries. CEL-SCI is also developing treatments for HIV/HPV coinfected patients with anal warts in collaboration with the U.S. Navy at the San Diego Naval Medical Center through a cooperative research and development agreement. The company operates its own 75,000 sq ft manufacturing facility near Baltimore, MD.

Expert Comments:

John Faessel, SmallCap Network (3/10/15)
"CEL-SCI Corporation's immunotherapy is on the cutting edge of cancer research and treatment today with solid success in Phase 1 and Phase 2 trials and creditable progress in the Phase 3 study that is at new highs in enrolment. Flat out—I think that there's a better than good chance of FDA approval in its Phase 3 endeavors . .the CEL-SCI fourth modality narrative is fascinating in its implications and a must to follow—and obviously it has truly uncommon investment potential."

Sharon di Stephano, Seeking Alpha (3/9/15)
"CEL-SCI Corporation's enrollment for Phase 3 trials in head and neck cancer have been increasing. . .I believe the company has a good chance of positioning itself well in cancer immunotherapy. . .CEL-SCI is ahead of many competitors, but not appreciated for its scientific and clinical work, presenting a strong opportunity to pick up shares at a very low price."

Yale Jen, Laidlaw & Company (3/4/15)
"We are reassuming our coverage of CEL-SCI Corporation with a Buy rating and $6/share target price to reflect the advancements of Multikine in head and neck cancer. . .accelerating patient recuritment for the Multikine Phase 3 study is a positive development."

Robert Wasserman, Dawson James Securities (3/2/15)
"CEL-SCI Corporation shares already trade considerably below the average market capitalization and enterprise value for stocks with a cancer therapeutic in Phase 3 trials. In addition, the company has a number of other hidden assets that boost its value. . .we are initiating coverage on CEL-SCI shares with a Buy rating and 12–18 month price target of $3/share."

Robert Wasserman, Dawson James Securities (2/20/15)
"CEL-SCI Corporation announced yesterday that the Ministry of Health for Malaysia has cleared that country for enrollment in the company's Phase 3 clinical trial of its Multikine immunotherapy treatment in head and neck cancer. Malaysia represents the twentieth country to approve the trial, with CEL-SCI targeting one more market for approval, or 21 total (including the U.S.)."

Management Q&A: View From the Top
Geert Kersten
Using immuno-therapies to treat cancers and autoimmune disorders has been limited. But that paradigm is changing, and CEL-SCI Corp. is among the companies poised to bring immunotherapy into these disease spaces.
read more >
John Faessel, SmallCap Network (2/18/15)
"CEL-SCI Corporation is well into Phase 3 trials for the treatment of head and neck cancer; there is a new high of 352 patients now enrolled in the Phase 3 study. By 2015E, a total of approximately 880 patients is expected to be enrolled through about 100 clinical centers in over 20 countries aside from those in the U.S.; it's the largest Phase 3 study for the treatment of head and neck cancers in the world."

More Comments

Experts Commenting on This Company


The information provided above is from analysts, newsletters and other contributors. Please contact the company and visit its website before making an investment decision.
CEL-SCI Corporation Content